Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R-2487 in Patients With Sjogren's Syndrome
NCT06297213Phase 1Not yet recruiting
- Sponsor
- Rise Therapeutics
- Start
- Nov 2026
- Primary completion
- Aug 2029
- Modality
- Nanoparticles, Yeast Strains, Device-based Delivery
01
Overview
Phase 1, open-label, single-arm trial of R-2487 in Sjogren's syndrome, sponsored by Rise Therapeutics. Primary endpoint: Adverse Events at 4 weeks. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
R-2487
03
Conditions
Sjogren's syndrome
Beyond the preview
Go deeper on NCT06297213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06297213.